Cargando…

Efficacy and safety of adding liraglutide to existing insulin regimens in Japanese patients with type 2 diabetes mellitus: A post‐hoc analysis of a phase 3 randomized clinical trial

AIMS/INTRODUCTION: To determine the efficacy and safety of adding liraglutide to three different insulin regimens in Japanese patients with type 2 diabetes mellitus. MATERIALS AND METHODS: In this post‐hoc analysis, results from a 36‐week, randomized, double‐blind, placebo‐controlled, parallel‐group...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kaneko, Shizuka, Nishijima, Keiji, Bosch‐Traberg, Heidrun, Kaku, Kohei, Seino, Yutaka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6031509/ https://www.ncbi.nlm.nih.gov/pubmed/29277968 http://dx.doi.org/10.1111/jdi.12793

Ejemplares similares

Safety and efficacy of the combination of the glucagon‐like peptide‐1 receptor agonist liraglutide with an oral antidiabetic drug in Japanese patients with type 2 diabetes: Post‐hoc analysis of a randomized, 52‐week, open‐label, parallel‐group trial
por: Kiyosue, Arihiro, et al.
Publicado: (2017)

Combination therapy with liraglutide and insulin in Japanese patients with type 2 diabetes: A 36‐week, randomized, double‐blind, parallel‐group trial
por: Seino, Yutaka, et al.
Publicado: (2016)

Liraglutide is effective and well tolerated in combination with an oral antidiabetic drug in Japanese patients with type 2 diabetes: A randomized, 52‐week, open‐label, parallel‐group trial
por: Kaku, Kohei, et al.
Publicado: (2015)

A randomized trial to investigate the efficacy and safety of once‐daily liraglutide 1.8 mg in Japanese adults with type 2 diabetes exhibiting an inadequate response to liraglutide 0.9 mg
por: Seino, Yutaka, et al.
Publicado: (2022)

The once‐daily human glucagon‐like peptide‐1 analog, liraglutide, improves β‐cell function in Japanese patients with type 2 diabetes
por: Seino, Yutaka, et al.
Publicado: (2012)

Liraglutide and Glycaemic Outcomes in the LEADER Trial
por: Zinman, Bernard, et al.
Publicado: (2018)

Efficacy and safety of luseogliflozin added to various oral antidiabetic drugs in Japanese patients with type 2 diabetes mellitus
por: Seino, Yutaka, et al.
Publicado: (2015)

Glucagon‐like peptide‐1 analog liraglutide in combination with sulfonylurea safely improves blood glucose measures vs sulfonylurea monotherapy in Japanese patients with type 2 diabetes: Results of a 52‐week, randomized, multicenter trial
por: Seino, Yutaka, et al.
Publicado: (2011)

Efficacy and safety of alogliptin added to sulfonylurea in Japanese patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled trial with an open‐label, long‐term extension study
por: Seino, Yutaka, et al.
Publicado: (2012)

Efficacy and safety of the fixed‐ratio combination of insulin degludec and liraglutide by baseline glycated hemoglobin, body mass index and age in Japanese individuals with type 2 diabetes: A subgroup analysis of two phase III trials
por: Komatsu, Mitsuhisa, et al.
Publicado: (2021)

Fifty‐two‐week, randomized, multicenter trial to compare the safety and efficacy of the novel glucagon‐like peptide‐1 analog liraglutide vs glibenclamide in patients with type 2 diabetes
por: Kaku, Kohei, et al.
Publicado: (2011)

Liraglutide use and evaluation of pancreatic outcomes in a US commercially insured population
por: Funch, Donnie, et al.
Publicado: (2019)

Risk of Thyroid Cancer Associated with Use of Liraglutide and Other Antidiabetic Drugs in a US Commercially Insured Population
por: Funch, Donnie, et al.
Publicado: (2021)

Effect of patient characteristics on the efficacy and safety of imeglimin monotherapy in Japanese patients with type 2 diabetes mellitus: A post‐hoc analysis of two randomized, placebo‐controlled trials
por: Hagi, Katsuhiko, et al.
Publicado: (2023)

Liraglutide in Adults with Type 2 Diabetes: Global Perspective on Safety, Efficacy and Patient Preference
por: Yabe, Daisuke, et al.
Publicado: (2011)

Efficacy and safety of once‐weekly semaglutide in Japanese individuals with type 2 diabetes by baseline age and body mass index
por: Yabe, Daisuke, et al.
Publicado: (2022)

A randomized, placebo‐controlled study to evaluate the efficacy and safety of adding omarigliptin to insulin therapy in Japanese patients with type 2 diabetes and inadequate glycaemic control
por: Kadowaki, Takashi, et al.
Publicado: (2021)

Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis
por: Rossing, Peter, et al.
Publicado: (2023)

Superior efficacy with a fixed‐ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin‐naïve Japanese patients with type 2 diabetes in a phase 3, open‐label, randomized trial
por: Kaku, Kohei, et al.
Publicado: (2019)

Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes
por: Seino, Yutaka, et al.
Publicado: (2017)

Sodium‐glucose cotransporter‐2 inhibitor luseogliflozin added to glucagon‐like peptide 1 receptor agonist liraglutide improves glycemic control with bodyweight and fat mass reductions in Japanese patients with type 2 diabetes: A 52‐week, open‐label, single‐arm study
por: Seino, Yutaka, et al.
Publicado: (2017)

Ad Hoc Discussion Session
por: Reich, Κ Η
Publicado: (1974)

Mobile ad hoc networking
por: Basagni, Stefano
Publicado: (2004)

Mobile Ad Hoc Networks
por: Loo, Jonathan, et al.
Publicado: (2011)

Vehicular ad-hoc networks
por: G, G
Publicado: (2020)

Ad hoc wireless networking
por: Xiuzhen Cheng, Xiuzhen, et al.
Publicado: (2003)

Acknowledgment of Ad Hoc Reviewers
por: Imperiale, Michael J.
Publicado: (2016)

Acknowledgment of Ad Hoc Reviewers
por: Imperiale, Michael J.
Publicado: (2017)

Acknowledgment of Ad Hoc Reviewers
por: Imperiale, Michael J.
Publicado: (2018)

Acknowledgment of Ad Hoc Reviewers
por: Gilbert, Jack A.
Publicado: (2018)

Acknowledgment of Ad Hoc Reviewers
por: Imperiale, Michael J.
Publicado: (2019)

Acknowledgment of Ad Hoc Reviewers
por: Gilbert, Jack A.
Publicado: (2019)

Acknowledgment of Ad Hoc Reviewers
por: Gilbert, Jack A.
Publicado: (2020)

Acknowledgment of Ad Hoc Reviewers
por: Imperiale, Michael J.
Publicado: (2020)

Receiver-Based Ad Hoc On Demand Multipath Routing Protocol for Mobile Ad Hoc Networks
por: Al-Nahari, Abdulaziz, et al.
Publicado: (2016)

Effects of DPP‐4 inhibitor linagliptin and GLP‐1 receptor agonist liraglutide on physiological response to hypoglycaemia in Japanese subjects with type 2 diabetes: A randomized, open‐label, 2‐arm parallel comparative, exploratory trial
por: Yabe, Daisuke, et al.
Publicado: (2016)

Long‐term efficacy and safety of canagliflozin in combination with insulin in Japanese patients with type 2 diabetes mellitus
por: Inagaki, Nobuya, et al.
Publicado: (2017)

Retrospective analysis of liraglutide and basal insulin combination therapy in Japanese type 2 diabetes patients: The association between remaining β‐cell function and the achievement of the glycated hemoglobin target 1 year after initiation
por: Usui, Ryota, et al.
Publicado: (2017)

Is a Switch From Insulin Therapy to Liraglutide Possible in Japanese Type 2 Diabetes Mellitus Patients?
por: Kawata, Takehiro, et al.
Publicado: (2014)

Insulin degludec in Japanese patients with type 1 diabetes mellitus: A randomized controlled trial
por: Iwamoto, Yasuhiko, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_pqqdhje8039ipa5c69nnolg08m